Justus Kaufmann, Isabel Krabbes, Eirini Nikolaidou, Nwabata Oji, Simone Ferdinandus, Julian Hlouschek, Georg Wurschi, Jan-Niklas Becker, Jana Schaule, Jörg-Andreas Müller, Laura Oebel, Felix Ehret, Christian Grad, Alexander Rühle
The rates of LRF and DF in this cohort are similar, and the highest risk for disease progression is within the first 3 years after treatment. Future analyses are needed to assess potential improvements with the use of induction and adjuvant systemic therapy.
PURPOSE: To determine oncological outcomes and patterns of recurrence of nasopharyngeal carcinoma (NPC) in a non-endemic population.
METHODS: MERLIN (DRKS00034782) is a retrospective study initiated by the Young DEGRO that included NPC patients who received definitive radiotherapy between 2004 and 2023. Overall survival (OS) and disease-free survival (DFS) were determined using Kaplan-Meier analyses, while the incidence of treatment failures was analyzed with death as a competing event. Prognostic variables were identified using Cox regression analyses.
RESULTS: Two hundred ninety-nine patients from 9 centers were analyzed; 274 (92%) were treated with concurrent systemic treatment, while 48 (16%) and 14 (5%) received induction and adjuvant chemotherapy. After a median follow-up of 62 months, 93 deaths, 40 local failures (LF), 19 regional failures (RF), and 41 distant failures (DF) were observed. Most LF (30/40), RF (15/19), and DF (38/41) occurred within the first 3 years after treatment. Five-year OS and DFS rates were 71% and 61%, while the 5‑year incidences of locoregional failures (LRF) and DF were 18% and 14%. In the multivariable analysis, age (HR, 1.03; 95% CI, 1.01-1.05), Karnofsky performance status (≤ 80% vs. ≥ 90%; HR, 1.97; 95%CI, 1.27-3.07), and AJCC/UICC stage (IV vs. I‑III; HR, 2.18; 95%CI, 1.42-3.35) were associated with DFS.
CONCLUSION: The rates of LRF and DF in this cohort are similar, and the highest risk for disease progression is within the first 3 years after treatment. Future analyses are needed to assess potential improvements with the use of induction and adjuvant systemic therapy.